MedTrace Logo

Non-interventional Study of Lenalidomide / Dexamethasone as First Line Therapy in Patients With Multiple Myeloma

NCT02537808 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 172

Last updated 2023-11-18

No results posted yet for this study

Summary

The objective of this non-interventional study is to explore the safety, effectiveness and quality of life of lenalidomide / dexamethasone as first line treatment for transplant-ineligible patients with multiple myeloma in a real life setting.

Conditions

Sponsors & Collaborators

  • iOMEDICO AG

    lead INDUSTRY

Principal Investigators

  • Holger Nückel, Professor · Hämatologisch-Onkologische Schwerpunktpraxis

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-23
Primary Completion
2020-09-30
Completion
2023-09-13

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02537808 on ClinicalTrials.gov